

Committee Advice Documents

Committee Advice documents summarise the advice the Committee has provided for the GM and novel foods regulated products applications where their advice was sought. They outline the areas they were asked to advise on and the conclusions reached, based on the evidence presented. These are used by the Food Standards Agency (FSA) and Food Standards Scotland (FSS) to inform the development of Safety Assessments which addresses the requirement in the legislation for an Opinion.

The completed Committee Advice Documents can be found below:

Calcidiol (25-hydroxycholecalciferol monohydrate) RP35

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Calcidiol \(25-hydroxycholecalciferol monohydrate\) RP35](#)

Synthetic cannabidiol (CBD) RP07

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Synthetic cannabidiol \(CBD\) RP07](#)

Cannabidiol (CBD) isolate - RP350

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Cannabidiol \(CBD\) isolate - RP350](#)

***Schizochytrium* sp. oil rich in DHA and EPA - RP 1411**

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Schizochytrium sp. oil rich in DHA and EPA](#)

Isomalto-oligosaccharides - RP1033

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Change of conditions of use for the novel food, isomalto-oligosaccharides](#)

Magnesium L-threonate - RP956

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Magnesium L-threonate as a novel food for use in food supplements](#)

Barley Rice Protein - RP19

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Barley Rice Protein - RP19](#)

Cetylated Fatty Acids - RP200

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Cetylated Fatty Acids - RP200](#)

3-fucosyllactose (3-FL) - RP1202

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[3-fucosyllactose \(3-FL\) - RP1202](#)

Lacto-N-fucopentaose I (LNFP-I) and 2'-fucosyllactose (2'-FL) - RP549

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Lacto-N-fucopentaose I \(LNFP-I\) and 2'-fucosyllactose \(2'-FL\) - RP549](#)